Obermatt
See Similar Stocks →

Charles River Laboratories

NYQ:CRL · US1598641074
Life Sciences Tools & ServicesX-Large

360

17
EV / EBIT80
Price / Owner Earnings100
Owner Earnings Yield1
Dividend Yield1
Price/Sales88
EV / Gross Profit61
Price/Book57
Return on Capital57
Cash Return on Capital37
Return on Equity30
EBIT Margin49
Gross Profitability49
Accruals62
Owner Earnings Margin37
Sales growth53
Profit Growth91
Long-Term EPS Growth40
Owner Earnings Growth5
Reinvestment26
Price momentum44
Debt load11
Refinancing91
Debt Payback1
Liquidity79
Analyst ratings18
Opinion Changes55
Price Target Upside43
Market mood43
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Charles River Laboratories doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
TypePublic Company
ExchangeNYSE
Founded1994
Employees11,156
Websitecriver.com
ISINUS1598641074
Last UpdateApr 2, 2026
Indices
S&P 500 (USA)D.J. US Health Care
Themes
Health DiagnosticsImmunologyChronic DiseasesRespiratoryGeneticsVaccinesOncologyBiotechnologyHealth CarePharmaceutical

Description

Charles River Laboratories International, Inc., together with its subsidiaries, operates as a full service, non-clinical global drug development partner. The company has built upon its original core competency of laboratory animal medicine and scien…

Analysis

Middle-of-the-road

Charles River Laboratories International, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is fragile. The company scores 4/20 on our value-creation score: not creating value.

Flags to be aware of: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
48
2023202420252026

All-time high

60

Mar 2026

All-time low

12

Jan 2025

Average rank

34

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
88
63
57
67
Price/Earnings
7
73
68
45
Price/Book
57
53
40
22
Dividend Yield
1
1
1
1
Value (overall)
22
63
51
37

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Charles River Laboratories with its peers
Inotiv
NAQ:NOTV
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
MaxCyte
NSQ:MXCT
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Acumen Pharmaceuticals
NSQ:ABOS
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Certara
NSQ:CERT
45
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →